Venture Capitals

By bringing innovative therapies to the patients, Venture Capitals aim to increase the value of their companies in the most efficient and fastest possible way. As any failure of a new drug candidate can lead to significant losses, at NUVISAN we understand the interest of de-risking the compound and optionally sharing the risk with you.
With a proven track-record of customer satisfaction, NUVISAN can partner with you to increase the value of your companies from today!

How Can We Support Venture Capitals Building Companies

NUVISAN can support building companies from very early stages both as specialist consultants for R&D and as executive partner for drug discovery and development. Our more than 400 scientists, with decades of experience in drug discovery and development, are able to perform whole integrated programs from target ID to clinical trials.

The Innovation Campus Berlin (ICB) has been running for many years to the benefit of a major pharmaceutical player. Now ICB is available to the industry for the first time from target identification to hit identification, hit-to-lead, lead optimization, DMPK profiling, selection of a pre-clinical candidate, up to IND enabling studies under GLP.

In addition, as scientific consultants, we will:

• De-risk projects and portfolios with tailor-made go/no-go experiments
• Offer selective support from expert staff to the team during the development phase
• Offer contributions from experts/consultants routinely working with big pharma and biotech, regulatory affairs, authorities (BfARM, PEI, Ethics Commission etc.).
• Consult on how to reach key pharma milestones for potential partnering
• Set-up efficient research plans to gain clarity on future challenges
• Evaluate reproducibility by wet lab activities to generate further value at high quality, in a timely manner, independent and unbiased

Due Diligence Stage

NUVISAN can support Venture Capitals already during the due diligence stage, as a specialist consulting partner. We can:

• Evaluate early ideas (proof of principle)
• Participate in investor-company discussion to challenge the team by independent specialists from the field
• Assess of compound specifics and chances of success, e.g. solubility etc. based on existing experiences
• Evaluate of existing data, e.g. trustability, plausibility, necessary breadth and depth
• Verify milestone planning/timing
• Calculate costs for milestones, e.g. forecast reasonable (e.g. regulatory affairs, laboratory costs)
• Reference to relevant experiences including failures – assuring confidentiality at all times